Courier Capital LLC Lowers Position in Pfizer Inc. (NYSE:PFE)

Courier Capital LLC cut its holdings in shares of Pfizer Inc. (NYSE:PFE) by 3.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 122,124 shares of the biopharmaceutical company’s stock after selling 4,241 shares during the quarter. Courier Capital LLC’s holdings in Pfizer were worth $3,516,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. Fulton Bank N.A. lifted its stake in Pfizer by 4.7% during the 3rd quarter. Fulton Bank N.A. now owns 176,239 shares of the biopharmaceutical company’s stock worth $5,846,000 after acquiring an additional 7,991 shares in the last quarter. Portside Wealth Group LLC acquired a new position in Pfizer during the 2nd quarter worth about $2,072,000. Adage Capital Partners GP L.L.C. lifted its stake in Pfizer by 40.5% during the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 4,739,672 shares of the biopharmaceutical company’s stock worth $157,215,000 after acquiring an additional 1,365,295 shares in the last quarter. Brookstone Capital Management lifted its stake in Pfizer by 88.5% during the 3rd quarter. Brookstone Capital Management now owns 452,352 shares of the biopharmaceutical company’s stock worth $14,109,000 after acquiring an additional 212,369 shares in the last quarter. Finally, ETF Store Inc. lifted its stake in Pfizer by 12.0% during the 3rd quarter. ETF Store Inc. now owns 6,803 shares of the biopharmaceutical company’s stock worth $214,000 after acquiring an additional 727 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

PFE has been the topic of a number of analyst reports. Argus lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. TD Cowen lowered Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target on the stock. in a research report on Thursday, January 4th. UBS Group reduced their price target on Pfizer from $34.00 to $27.00 and set a “neutral” rating on the stock in a research report on Thursday, December 14th. Truist Financial reduced their price target on Pfizer from $42.00 to $36.00 and set a “buy” rating on the stock in a research report on Thursday, December 14th. Finally, Barclays reduced their price target on Pfizer from $34.00 to $28.00 and set an “equal weight” rating on the stock in a research report on Thursday, December 14th. Twelve research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $36.88.

Pfizer Trading Up 0.7 %

NYSE:PFE opened at $27.77 on Thursday. The stock’s 50 day moving average price is $27.47 and its 200 day moving average price is $29.47. The company has a market capitalization of $157.25 billion, a PE ratio of 77.14, a P/E/G ratio of 1.24 and a beta of 0.61. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. Pfizer Inc. has a 52-week low of $25.61 and a 52-week high of $42.22.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. The firm had revenue of $14.25 billion for the quarter, compared to the consensus estimate of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The firm’s quarterly revenue was down 41.3% compared to the same quarter last year. During the same quarter last year, the business posted $1.14 EPS. On average, research analysts anticipate that Pfizer Inc. will post 2.22 EPS for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.